Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients

Nephron

Volumn 72, Issue 4, 1996, Pages 723-724

  Lago, M ^a   Perez Garcia, R ^a   Garcia de Vinuesa, M S ^a   Anaya, F ^a   Valderrdbano, F ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; LETTER; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROPOIETIN; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS;

EID: 0029870176     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000188977     Document Type: Article

References (5)

1. Winearls G., Oliver D, Pippard M., Reid C., Downing M., Cotes P: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis., Lancet 1986;Vol ii: 1175-1178.
2. Eschbach J., Egrie J, Downing M., Browne J., Adamson J: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin., N Engl J Med 1987:316:73-78.
3. Horl WH; Optimal route of administration of erythropoietin in chronic renal failure patients: Intravenous versus subcutaneous., Acta Hae-matologica 1992:87(suppl 1): 16-19.
4. Lui SF, Wong KC, Li Ph K.T., Lai KN: Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients., Am J Nephrol 1992:12:55-60.
5. Lui SF, Law CB, Ting SM, Lai KN: Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis., Clin Nephrol 1991:36:246-251